NCT00499538已完成1 期
A Single Dose Bioavailability Study of 3 New Formulations of SKI-606 (500 mg) Compared With a Reference Capsule and an Oral Solution in Healthy Adult Subjects
Wyeth is now a wholly owned subsidiary of Pfizer1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2007年7月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- The data from this study along with in vitro data will be used to explore in vitro/in vivo correlation for SKI-606 to support formulation development.
研究概览
简要总结
To evaluate the comparative bioavailability of 3 new tablet formulations of SKI-606 with a reference capsule and an oral solution in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male and female aged 18 to 50 years.
- •Women of nonchildbearing potential (WONCBP).
排除标准
- 未提供
结局指标
主要结局
The data from this study along with in vitro data will be used to explore in vitro/in vivo correlation for SKI-606 to support formulation development.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study Comparing 2 New Formulations of HKI-272 in Healthy Adult SubjectsHealthyNCT00498745Puma Biotechnology, Inc.36
已完成
1 期
Relative Bioavailability Study of Candesartan Cilexetil Under Fasting ConditionsCardiovascular DiseaseNCT02254447GlaxoSmithKline18
已完成
1 期
Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mgChagas DiseaseNCT03350295Bayer48
已完成
1 期
Study of New Tablet Formulations and Suspension Formulation Compared to Current (1B) Formulation of BILR 355 BS in Healthy Male Volunteer SubjectsHealthyNCT02259868Boehringer Ingelheim88
已完成
1 期
Bioavailability and Effect of Food on TAK-385 Tablet Formulations in Healthy ParticipantsHealthy VolunteersNCT02396147Takeda54